Anti-Matrix protein 1 antibody [GA2B] (ab22396)
- Datasheet
- References (13)
- Protocols
Overview
-
Product nameAnti-Matrix protein 1 antibody [GA2B]
See all Matrix protein 1 primary antibodies -
DescriptionMouse monoclonal [GA2B] to Matrix protein 1
-
Host speciesMouse
-
Tested applicationsSuitable for: Flow Cyt, IHC-P, WB, ICC/IFmore details
-
Species reactivityReacts with Influenza A. Not yet tested in other species.
-
Immunogen
Tissue/ cell preparation- Influenza A/ Puerto Rico/ 8/ 34 (H1N1) and A/Bangkok/ 1/ 79 (H3N2) viruses
Properties
-
FormLiquid
-
Storage instructionsShipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid freeze / thaw cycles.
-
Storage bufferpH: 7.50
Preservative: 0.09% Sodium azide
Constituent: PBS -
Concentration information loading... -
PurityProtein A purified
-
ClonalityMonoclonal
-
Clone numberGA2B
-
MyelomaP3x63-Ag8.653
-
IsotypeIgG1
-
Research areas
Associated products
-
Compatible Secondaries
-
Conjugation kits
-
Isotype control
Applications
Our Abpromise guarantee covers the use of ab22396 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
| Application | Abreviews | Notes |
|---|---|---|
| Flow Cyt | Use at an assay dependent concentration. PubMed: 20413723 ab170190 - Mouse monoclonal IgG1, is suitable for use as an isotype control with this antibody.
|
|
| IHC-P | Use at an assay dependent concentration. | |
| WB | Use at an assay dependent concentration. | |
| ICC/IF | 1/100. |
Target
-
RelevanceInfluenza virus type A matrix protein, also known as M1, is composed of a 252 amino acid sequence and is type-specific in influenza viruses. It is located inside the viral lipid envelope and plays a key role in virus assembly and replication. M1 can be isolated from particles by removing the envelope with detergents and reducing the pH to 4.0. Influenza viruses are a common and widely spread infectious agent. Like many other viruses, influenza virus are constantly undergoing mutations and thereby avoiding the immune system. The Influenza A Virus M proteins form a continuous shell on the inner side of the lipid bilayer, maintaining the structural integrity of the virus particle through hydrophobic interactions.
-
Cellular localizationCytoplasmic
-
Alternative names
- M1 antibody
- Matrix Protein 1 antibody
- Matrix Protein I antibody
- Membrane matrix protein M1 antibody
Images
-
![Flow Cytometry - Anti-Matrix protein 1 antibody [GA2B] (ab22396)](https://www.abcam.com/ps/products/22/ab22396/Images/Influenza-A-Virus-M1-Primary-antibodies-ab22396-9.jpg)
Flow Cytometry - Anti-Matrix protein 1 antibody [GA2B] (ab22396)Image courtesy of an anonymous Abreview.ab22396 used in Flow Cytometry.
Influenza infected A549 cells were trypsinized, fixed in paraformaldehyde, permeabilized and then incubated with ab22396 for analysis by Flow Cytometry.
ab22396 used at a 1/200 dilution.The secondary used was ab96874, diluted 1/200. -
![Immunocytochemistry/ Immunofluorescence - Anti-Matrix protein 1 antibody [GA2B] (ab22396)](https://www.abcam.com/ps/products/22/ab22396/Images/Influenza-A-Virus-M1-Primary-antibodies-ab22396-10.jpg)
Immunocytochemistry/ Immunofluorescence - Anti-Matrix protein 1 antibody [GA2B] (ab22396)Image from Chase GP et al., PLoS Pathog. 2011 Sep;7(9):e1002187. Epub 2011 Sep 1.Fig 4.; doi:10.1371/journal.ppat.1002187; September 1, 2011, PLoS Pathog 7(9): e1002187.Immunofluorescence analysis of HeLa cells staining Influenza A Virus M1 using ab22396.
Cells were treated with either 20 µg/ml Prostaglandin A (PGA) or EtOH vehicle control, 3 hours post infection by Influenza A Virus, then fractionated at 9 hours post infection before analysis by immunofluorescence.
Protocols
References
This product has been referenced in:
- Desforges JP et al. Environmental contaminant mixtures modulate in vitro influenza infection. Sci Total Environ 634:20-28 (2018). Flow Cyt . Read more (PubMed: 29626767) »
- Nogales A et al. Rearrangement of Influenza Virus Spliced Segments for the Development of Live-Attenuated Vaccines. J Virol 90:6291-302 (2016). WB . Read more (PubMed: 27122587) »
